Exicure Inc (XCUR)

$4.17 -0.01 (-0.24%)
Market Cap 26.35M
Revenue (ttm) 500,000.00
Net Income (ttm) -9.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,940.00%
Debt to Equity Ratio 0.00
Volume 27,900
Avg Vol 45,944
Day's Range N/A - N/A
Shares Out 6.32M
Stochastic %K 65%
Beta 3.76
Analysts Strong Buy
Price Target $2.00

Company Profile

Exicure, Inc. does not have significant operations. Previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 847 673 1700
Address:
400 Seaport Court, Suite 102, Redwood City, United States
MarketAttack
MarketAttack Sep. 26 at 2:36 PM
$XCUR time to fly
0 · Reply
HustlerTV
HustlerTV Sep. 24 at 9:53 PM
AMS the next penny stock gapper tomorrow, low float with no dilution and undervalued! $XPON $AKTX $AQMS $ZONE $XCUR watching these
1 · Reply
MarketAttack
MarketAttack Sep. 19 at 1:58 PM
$XCUR Back to 12$ Incredible news are coming
0 · Reply
MarketAttack
MarketAttack Sep. 18 at 2:14 PM
$XCUR go to 10$
0 · Reply
KunalSingh
KunalSingh Sep. 16 at 4:06 PM
I don’t have much hope for small caps boomed stock unless they crack a Phase 1, 2, or 3 trial. Last year I traded $XCUR, which did a similar debt-to-stock deal to clean up their books. I waited patiently as the stock moved from $2.1 → $1.4 → $6 → $4 → $10, and eventually hit $33. I played it a few times, but the key win was validating my trading thesis which matters more than random scalping gains.
0 · Reply
MarketAttack
MarketAttack Sep. 16 at 2:00 PM
$XCUR to 10$ this week
1 · Reply
MarketAttack
MarketAttack Sep. 15 at 11:41 PM
$XCUR Journey back to 10$...has just started
0 · Reply
MarketAttack
MarketAttack Sep. 15 at 5:48 PM
$XCUR go monster...your time is coming
0 · Reply
MarketAttack
MarketAttack Sep. 15 at 5:00 PM
$XCUR go beast go
0 · Reply
MarketAttack
MarketAttack Sep. 15 at 4:41 PM
$XCUR Very bullish on that from here...long and holding
0 · Reply
Latest News on XCUR
Exicure, Inc. Reports Second Quarter 2025 Financial Results

Aug 8, 2025, 4:01 PM EDT - 2 months ago

Exicure, Inc. Reports Second Quarter 2025 Financial Results

Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements

Aug 4, 2025, 4:37 PM EDT - 2 months ago

Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements

Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Aug 1, 2025, 4:01 PM EDT - 2 months ago

Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Exicure, Inc. Reports First Quarter 2025 Financial Results

Jun 27, 2025, 4:01 PM EDT - 3 months ago

Exicure, Inc. Reports First Quarter 2025 Financial Results

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

May 28, 2025, 4:58 PM EDT - 4 months ago

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

May 5, 2025, 8:00 AM EDT - 5 months ago

Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

Apr 14, 2025, 6:11 PM EDT - 6 months ago

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

Apr 11, 2025, 7:42 PM EDT - 6 months ago

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

Exicure, Inc. Reports Full Year 2024 Financial Results

Mar 18, 2025, 4:01 PM EDT - 7 months ago

Exicure, Inc. Reports Full Year 2024 Financial Results

Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia

Mar 13, 2025, 4:08 PM EDT - 7 months ago

Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia

CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Jan 23, 2025, 12:17 AM EST - 9 months ago

CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Jan 22, 2025, 4:01 PM EST - 9 months ago

Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech

Dec 26, 2024, 8:08 PM EST - 10 months ago

Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech

CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Dec 21, 2024, 1:48 PM EST - 10 months ago

CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Dec 20, 2024, 4:42 PM EST - 10 months ago

Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results

Nov 14, 2024, 4:01 PM EST - 11 months ago

Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results

Exicure, Inc. Receives Extension from Nasdaq Hearings Panel

Sep 18, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Receives Extension from Nasdaq Hearings Panel

Exicure, Inc. Announces 1-for-5 Reverse Stock Split

Aug 26, 2024, 9:08 AM EDT - 1 year ago

Exicure, Inc. Announces 1-for-5 Reverse Stock Split

Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting

Aug 19, 2024, 10:31 AM EDT - 1 year ago

Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting

Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting

Aug 15, 2024, 10:31 AM EDT - 1 year ago

Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting

Exicure, Inc. Reports Second Quarter 2024 Financial Results

Aug 13, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Reports Second Quarter 2024 Financial Results

Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics

Aug 8, 2024, 4:27 PM EDT - 1 year ago

Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics

Exicure, Inc. Receives Positive Listing Determination from Nasdaq

Aug 1, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Receives Positive Listing Determination from Nasdaq

Exicure, Inc. Reports First Quarter 2024 Financial Results

Jun 17, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Reports First Quarter 2024 Financial Results

Exicure, Inc. Reports Full Year 2023 Financial Results

Jun 6, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Reports Full Year 2023 Financial Results

Exicure, Inc. Received Nasdaq Notice of a Delisting Determination

May 23, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Received Nasdaq Notice of a Delisting Determination

Exicure, Inc. Reports Third Quarter 2023 Financial Results

May 16, 2024, 4:08 PM EDT - 1 year ago

Exicure, Inc. Reports Third Quarter 2023 Financial Results

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K

Apr 22, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K

Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis

Feb 5, 2024, 4:01 PM EST - 1 year ago

Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis

Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors

Aug 23, 2023, 9:48 AM EDT - 2 years ago

Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors

Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 11, 2023, 4:01 PM EDT - 2 years ago

Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update

Jul 14, 2023, 4:01 PM EDT - 2 years ago

Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update

Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives

May 26, 2023, 4:01 PM EDT - 2 years ago

Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives

Exicure, Inc. Announces Investment in Korean SNS Platform Cyworld

May 4, 2023, 4:01 PM EDT - 2 years ago

Exicure, Inc. Announces Investment in Korean SNS Platform Cyworld

Exicure, Inc. Reports Full Year 2022 Financial Results and Provides Corporate Update

Mar 27, 2023, 4:01 PM EDT - 2 years ago

Exicure, Inc. Reports Full Year 2022 Financial Results and Provides Corporate Update

Exicure, Inc. Announces Closing of Private Placement Transaction with CBI USA, Inc. and Changes to the Board of Directors

Feb 24, 2023, 5:10 PM EST - 2 years ago

Exicure, Inc. Announces Closing of Private Placement Transaction with CBI USA, Inc. and Changes to the Board of Directors

Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements

Dec 14, 2022, 5:00 AM EST - 3 years ago

Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements

Exicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 14, 2022, 4:01 PM EST - 3 years ago

Exicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Exicure, Inc. Enters Into Definitive Agreement With CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives

Sep 26, 2022, 4:01 PM EDT - 3 years ago

Exicure, Inc. Enters Into Definitive Agreement With CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives

Exicure Announces Presentation at Chardan's 6th Annual Genetic Medicines Conference

Sep 1, 2022, 7:00 AM EDT - 3 years ago

Exicure Announces Presentation at Chardan's 6th Annual Genetic Medicines Conference

Exicure, Inc. Reports Second Quarter 2022 Financial Results and Corporate Progress

Aug 15, 2022, 4:01 PM EDT - 3 years ago

Exicure, Inc. Reports Second Quarter 2022 Financial Results and Corporate Progress

Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jul 20, 2022, 4:01 PM EDT - 3 years ago

Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

Exicure, Inc. Announces Receipt of Nasdaq Notice of Non-compliance and Implementation of One-for-Thirty Reverse Stock Split

Jun 29, 2022, 12:00 PM EDT - 3 years ago

Exicure, Inc. Announces Receipt of Nasdaq Notice of Non-compliance and Implementation of One-for-Thirty Reverse Stock Split

Exicure, Inc. Announces Adjournment of Annual Meeting of Stockholders

May 27, 2022, 4:01 PM EDT - 3 years ago

Exicure, Inc. Announces Adjournment of Annual Meeting of Stockholders

Exicure Announces Presentation at 2022 H.C. Wainwright Global Life Sciences Conference

May 17, 2022, 7:00 AM EDT - 3 years ago

Exicure Announces Presentation at 2022 H.C. Wainwright Global Life Sciences Conference

Exicure, Inc. Reports First Quarter 2022 Financial Results and Corporate Progress

May 16, 2022, 4:01 PM EDT - 3 years ago

Exicure, Inc. Reports First Quarter 2022 Financial Results and Corporate Progress

Exicure Announces $5 Million Raise in Private Placement Transaction Priced at Market Premium

May 10, 2022, 7:21 PM EDT - 3 years ago

Exicure Announces $5 Million Raise in Private Placement Transaction Priced at Market Premium

Exicure to Present at Upcoming TIDES USA Oligonucleotide & Peptide Therapeutics Conference

May 9, 2022, 7:00 AM EDT - 3 years ago

Exicure to Present at Upcoming TIDES USA Oligonucleotide & Peptide Therapeutics Conference

Exicure Shares Plunge After Q4 Results Included A Going Concern Risk

Mar 28, 2022, 10:31 AM EDT - 3 years ago

Exicure Shares Plunge After Q4 Results Included A Going Concern Risk

Exicure, Inc. Reports Full Year 2021 Financial Results and Corporate Progress

Mar 25, 2022, 4:15 PM EDT - 3 years ago

Exicure, Inc. Reports Full Year 2021 Financial Results and Corporate Progress

MarketAttack
MarketAttack Sep. 26 at 2:36 PM
$XCUR time to fly
0 · Reply
HustlerTV
HustlerTV Sep. 24 at 9:53 PM
AMS the next penny stock gapper tomorrow, low float with no dilution and undervalued! $XPON $AKTX $AQMS $ZONE $XCUR watching these
1 · Reply
MarketAttack
MarketAttack Sep. 19 at 1:58 PM
$XCUR Back to 12$ Incredible news are coming
0 · Reply
MarketAttack
MarketAttack Sep. 18 at 2:14 PM
$XCUR go to 10$
0 · Reply
KunalSingh
KunalSingh Sep. 16 at 4:06 PM
I don’t have much hope for small caps boomed stock unless they crack a Phase 1, 2, or 3 trial. Last year I traded $XCUR, which did a similar debt-to-stock deal to clean up their books. I waited patiently as the stock moved from $2.1 → $1.4 → $6 → $4 → $10, and eventually hit $33. I played it a few times, but the key win was validating my trading thesis which matters more than random scalping gains.
0 · Reply
MarketAttack
MarketAttack Sep. 16 at 2:00 PM
$XCUR to 10$ this week
1 · Reply
MarketAttack
MarketAttack Sep. 15 at 11:41 PM
$XCUR Journey back to 10$...has just started
0 · Reply
MarketAttack
MarketAttack Sep. 15 at 5:48 PM
$XCUR go monster...your time is coming
0 · Reply
MarketAttack
MarketAttack Sep. 15 at 5:00 PM
$XCUR go beast go
0 · Reply
MarketAttack
MarketAttack Sep. 15 at 4:41 PM
$XCUR Very bullish on that from here...long and holding
0 · Reply
MarketAttack
MarketAttack Sep. 15 at 4:40 PM
$XCUR A journey to 10$ back is starting
0 · Reply
GluttonBoy
GluttonBoy Sep. 9 at 5:53 PM
TAIT stock is at zero borrow with shorts trapped and about to have a historic squeeze 3M float with no dilution and is a profitable semiconductor play $XCUR $AIRG $NRSN $PC $EONR on watch rn
0 · Reply
GluttonBoy
GluttonBoy Sep. 9 at 5:27 PM
TAIT stock is at zero borrow with shorts trapped and about to have a historic squeeze 3M float with no dilution and is a profitable semiconductor play Also looking at : $LITB $XCUR $SSKN $SJ $NYC
0 · Reply
TheUnmaker
TheUnmaker Sep. 8 at 4:50 PM
$XCUR Waiting on this beast.
1 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 5 at 5:18 PM
$XCUR Really good write-up that perfectly summarizes XCUR's present situation. So if you want to bring your XCUR knowledge up to date or just discover XCUR, this is required reading. https://beyondspx.com/quote/XCUR/exicure-s-uncharted-path-biotech-pivot-and-diversified-ventures-nasdaq-xcur#analysis
0 · Reply
Champ2022
Champ2022 Aug. 29 at 3:32 PM
$XCUR double bottom, should reverse and go up, right?!
1 · Reply
topstockalerts
topstockalerts Aug. 27 at 12:40 PM
$XCUR look who’s up.. ⬆️
0 · Reply
Champ2022
Champ2022 Aug. 23 at 3:11 PM
$XCUR bounce off of $5.59 or sooner? This stock wakes up and rolls, hopefully soon
0 · Reply
Champ2022
Champ2022 Aug. 15 at 3:31 PM
$XCUR this one moves up fast, moves down slow, it’s due to blast IMO
0 · Reply
Champ2022
Champ2022 Aug. 14 at 5:46 PM
$XCUR why is the ticker stuck on 7 even for so long?
0 · Reply
edvquye
edvquye Aug. 4 at 3:32 PM
$XCUR in $7.00
1 · Reply